Fig. 5
[13C]-labeled metabolite tracing analysis. A Schematic showing metabolites labeled by [U-13C]-glucose (GLC) or [U-13C]-glutamine (GLN) after treatment of A375R1 cells with vehicle (V), IACS (I), STN (S), or their combination (I + S) for 12 h. B Fractional labeling of glycolysis pathway metabolites glucose-6-phosphate (G6P), phosphoenolpyruvate (PEP), and pyruvate (PYR) by [U-13C]-GLC (glucose) following treatment with IACS (I) and STN (S) or their combination (I + S). C and D Fractional labeling of TCA cycle metabolites, citrate (CIT), α-ketoglutarate (αKGA), and succinate (SUC) by [U13C]-GLC (C) and [U-13C]-GLN (glutamine) (D). E and F Fractional labeling of acetyl CoA (Ac-CoA) by [U13C]-GLC (E) and [U-13C]-GLN (F). G and H Fractional labeling of HMG-CoA and mevalonate (MEV) by [U13C]-GLC (G) and [U-13C]-GLN (H). I and J Fractional labeling of malonyl CoA (Mal-CoA) and lipoic acid (LIPO) by [U13C]-GLC (I) and [U-13C]-GLN (J). Y-axis represents normalized relative fractional abundances of 13C-isotopologues, and x-axis represents indicated treatments. Data is average of triplicates and error bars SD